5th November 2025
Krishgen Biosystems, a global developer and manufacturer of ELISA kits for pharmacokinetic (PK), anti-drug antibody (ADA), and biocompatibility studies, is proud to announce its participation in a World Health Organization (WHO) and National Institute for Biological Standards and Control (NIBSC) collaborative study focused on the standardization of anti-Adalimumab antibodies.
As part of the global network of 22 participating laboratories, Krishgen performed quantification using our Anti-Adalimumab ELISA kits. This milestone represents a fullcircle moment for Krishgen Biosystems – a company that routinely and proudly uses NIBSC standards for in-house validation and assay calibration. Participating in the development of a new standard exemplifies Krishgen’s position at the intersection of biologic assay innovation and global harmonization.
“We are honored to have contributed to this international initiative that strengthens assay standardization for biologics,” said Dr Kalpesh Jain, CEO, Krishgen Biosystems.
“Our ELISA kits are designed for reproducibility and accuracy in PK and ADA workflows, and contributing data to this effort reinforces our ongoing commitment to scientific rigor and comparability across laboratories.”